- Home
- ACAD vs AG Comparison
ACAD vs AG Comparison
Compare ACAD & AG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- AG
- Stock Information
- Founded
- ACAD 1993
- AG 1979
- Country
- ACAD United States
- AG Canada
- Employees
- ACAD N/A
- AG N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- AG Precious Metals
- Sector
- ACAD Health Care
- AG Basic Materials
- Exchange
- ACAD Nasdaq
- AG Nasdaq
- Market Cap
- ACAD 3.5B
- AG 4.0B
- IPO Year
- ACAD 2004
- AG N/A
- Fundamental
- Price
- ACAD $23.53
- AG $7.84
- Analyst Decision
- ACAD Buy
- AG Buy
- Analyst Count
- ACAD 18
- AG 2
- Target Price
- ACAD $27.94
- AG $9.63
- AVG Volume (30 Days)
- ACAD 1.7M
- AG 18.5M
- Earning Date
- ACAD 08-06-2025
- AG 08-14-2025
- Dividend Yield
- ACAD N/A
- AG 0.25%
- EPS Growth
- ACAD N/A
- AG N/A
- EPS
- ACAD 1.37
- AG N/A
- Revenue
- ACAD $996,283,000.00
- AG $698,532,000.00
- Revenue This Year
- ACAD $13.28
- AG $89.62
- Revenue Next Year
- ACAD $10.88
- AG N/A
- P/E Ratio
- ACAD $17.19
- AG N/A
- Revenue Growth
- ACAD 22.42
- AG 33.60
- 52 Week Low
- ACAD $13.40
- AG $4.43
- 52 Week High
- ACAD $25.23
- AG $9.48
- Technical
- Relative Strength Index (RSI)
- ACAD 61.47
- AG 40.83
- Support Level
- ACAD $22.40
- AG $8.14
- Resistance Level
- ACAD $24.06
- AG $8.42
- Average True Range (ATR)
- ACAD 0.72
- AG 0.34
- MACD
- ACAD 0.09
- AG -0.14
- Stochastic Oscillator
- ACAD 76.96
- AG 6.51
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.